Data on the use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) were not available in the database, although both classes are recommended as first-line therapy in current hypertension guidelines. This evidence concerns the gene ACE and Hypertension.